Large-scale reorganization begins March 18, 2019
Sometimes, something seems so obvious you think everyone sees it.
Designed for the crowded home healthcare market.
FDA announces several new initiatives affecting medical device manufacturers.
And we were just getting used to ICD-10.
First genetically-engineered immunotherapy approved by the FDA.
Dashboards include data for Medicare Part B, Medicare Part D, and Medicaid.
Pharmaceutical manufacturers, pharmacy benefits managers and insurers square off.
If the new rules make it through the comment period, patients, acute and long term care hospitals, and certain out-of-network specialists will see big changes.
“To become comfortable with uncertainty is one of the primary goals in the training of a physician.”
At the corner of pharma and technology – the future of product development?
Major drivers are prices of labor and goods, and administrative costs.
Ending tax breaks to oil and gas companies would replace the lost tax revenue.
They know it’s a problem, just not a high priority.
Building better circuitry with bacteria.